RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) 是一家生物製藥公司，主要專注于開發幷銷售炎症性疾病和胃腸疾病及癌症治療方面的處于後期臨床試驗階段的專有口服小分子藥物。本公司今天宣布12毫克BEKINDA™治療腹瀉型腸易激綜合征的二期臨床試驗的首位患者已經用藥。
隨機雙盲安慰劑對照二期臨床試驗預計將在美國12個臨床點招募120名受試者，旨在評估12毫克BEKINDA™用于治療腹瀉型腸易激綜合征患者的安全性和療效。
腸易激綜合征是最常見的胃腸疾病之一，據估測美國有至少3000萬人受該病困擾，其中50%以上患者患的是腹瀉型腸易激綜合征。
BEKINDA™ 是專有的止吐藥昂丹司瓊的緩釋口服藥片製劑，日服一次，靶向爲多種胃腸適應症。RedHill正在進行24毫克和12毫克兩種劑量的BEKINDA™臨床試驗，用于不同的適應症。24毫克BEKINDA™治療急性胃腸炎和慢性胃炎的三期試驗（GUARD試驗）正在美國進行中，預計將在2016年年底發布試驗結果。
RedHill Biopharma Ltd介紹：
RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) 是一家總部位于以色列的新興生物醫藥公司，主要專注于開發幷銷售治療炎症性疾病和腸胃疾病以及癌症方面的處于後期臨床試驗階段的專有口服小分子藥。 公司目前的産品管綫包括：(i) RHB-105 -治療幽門螺杆菌感染的口服混合藥，首個三期試驗獲得成功；(ii) RHB-104 -治療克羅恩病的口服混合藥，正在進行首個三期試驗以及治療多發性硬化症的二a期概念驗證試驗；(iii) BEKINDA™ (RHB-102) -日服一次的昂丹司瓊口服藥片製劑，正在美國進行治療急性腸胃炎和慢性胃炎的三期試驗，以及治療腹瀉型腸易激綜合征的二期試驗；(iv) RHB-106 -腸道準備藥物膠囊，已經授權給Salix Pharmaceuticals Ltd.；(v) YELIVA™ (ABC294640) -二期階段的口服SK2選擇性抑制劑，是首創新藥，靶向爲多種腫瘤、炎症性和胃腸道適應症；(vi) MESUPRON® – 處于二期試驗階段的uPA抑制劑口服膠囊，是首創新藥，靶向爲胃腸和其他實體瘤；(vii) RP101 – Hsp27抑制劑口服藥片，是處于二期試驗階段的首創新藥，靶向爲胰腺癌和其他胃腸癌，RedHill擁有該藥物的收購選擇權；(viii) RIZAPORT™ (RHB-103) -利扎曲坦口服薄膜製劑，用于治療急性偏頭痛，正在與美國食品藥品監督管理局討論新藥申請，2015年10月獲准在德國上市；以及(ix) RHB-101 -心血管藥物卡維地洛日服一次的口服藥片製劑。
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (viii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xii) competitive companies and technologies within the Company’s industry; and (xiii) the impact of the political and security situation in Israel on the Company’s business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on February 25, 2016. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.
公司連絡人：
Adi Frish
業務發展和許可高級副總裁
RedHill Biopharma
+972-54-6543-112
[email protected]
投資者關係連絡人（美國）：
Marcy Nanus
高級副總裁
The Trout Group
+1-646-378-2927
[email protected]
北美投資訊息有限公司將於2016年6月23日隆重召開
生命科學年度國際金融投資博覽會 – 2016上海會展
更多會展詳情，參展企業，登記註冊等信息詳見:
